Compare CVS Health Corp (CVS) vs Rocket Lab USA Inc (RKLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Rocket Lab USA Inc — how do they compare? CVS Health Corp trades at $85.46 (market cap $112.29B), while Rocket Lab USA Inc trades at $69.56 (market cap $43.74B). The key difference: CVS Health Corp is far larger — about 2.6× Rocket Lab USA Inc's market cap, and CVS Health Corp pays a 3.03% dividend while Rocket Lab USA Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Rocket Lab USA Inc for 29 Days on average.
| CVS | RKLB | |
|---|---|---|
Market Cap | $112.29B | $43.74B |
Volume | 7,763,676 | 22,892,581 |
Sector | Health | Industrials |
52-Week High | $110.60 | $150.23 |
52-Week Low | $70.08 | $39.48 |
Typical Hold Time | 83 Days | 29 Days |
Enterprise Value | $174.64B | $41.57B |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats in Q1 and Q2 2026, alongside steady revenue growth to $402.07B in 2025, highlight operational strength. The stock's valuation appears attractive with a P/E of 23.17 and P/S of 0.27, while a consensus price target of $111.20 suggests significant upside potential. Positive news includes Aetna's 2027 Medicare plan enhancements and a declared quarterly dividend.
The outlook for CVS remains positive, driven by earnings momentum and strategic initiatives in healthcare services. Key risks include reimbursement pressures and regulatory scrutiny, but Wall Street's 85% buy rating and institutional interest underscore confidence. Investors should weigh the stock's growth prospects against margin volatility and debt levels, with the current price offering a favorable entry point relative to targets.
Rocket Lab (RKLB) trades at $71.92, down 4.18% today, with neutral technical signals and strong analyst support. The company recently secured its largest commercial Electron deal - 20 launches with Synspective - boosting its backlog past 100 missions. Despite negative profitability metrics, revenue growth continues with 2026 projections showing improvement from 2025's $602 million. The stock trades at elevated valuation multiples with P/S of 51.96 and P/B of 12.52.
RKLB presents a growth story with significant contract wins and expanding launch capacity, though profitability remains elusive. The 76% analyst buy rating and $107 consensus target suggest substantial upside potential. Key risks include intense SpaceX competition, high cash burn, and valuation concerns. Investors must weigh growth trajectory against persistent losses and competitive pressures in the evolving space industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →
